Targeting cell death and survival receptors in hepatocellular carcinoma

Anti-Cancer Agents in Medicinal Chemistry

Volumn 11, Issue 6, 2011, Pages 576-584

  Muntané, Jordi ^a,b  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Apoptosis; Cancer; CD95; Cell death receptors; TNF; Trail

Indexed keywords

ADALIMUMAB; BLEOMYCIN; CARBOPLATIN; CONATUMUMAB; DEATH RECEPTOR; DOXORUBICIN; DROZITUMAB; FAS ANTIGEN; FAS LIGAND; FLICE INHIBITORY PROTEIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; IRINOTECAN; LEXATUMUMAB; MAPATUMUMAB; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MITOXANTRONE; PACLITAXEL; PROTEIN P53; SORAFENIB; TIGATUZUMAB; TUMOR MARKER; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CELL SURVIVAL; COMPLEMENT DEPENDENT CYTOTOXICITY; CYTOKINE RELEASE; DEGRANULATION; DISEASE COURSE; DNA POLYMORPHISM; LIVER CELL CARCINOMA; LIVER METASTASIS; MOLECULARLY TARGETED THERAPY; NONHODGKIN LYMPHOMA; PHAGOCYTOSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; SOLID TUMOR; TUMOR VOLUME;

EID: 79959315992     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152011796011082     Document Type: Article

References (135)

1. Zhivotovsky, B.; Kroemer, G. Apoptosis and genomic instability. Nat. Rev. Mol. Cell Biol., 2004, 5, 752-762.
2. Bhardwaj, A.; Aggarwal, B.B. Receptor-mediated choreography of life and death. J. Clin. Immun., 2003, 23, 317-332.
3. Naismith, J.H.; Sprang, S.R. Modularity in the TNF-receptor family. Trends in Biochem. Sci., 1998, 23, 74-79.
4. Bodmer, J.L.; Schneider, P.; Tschopp, J. The molecular architecture of the TNF superfamily. Trends in Biochem.Sci., 2002, 27, 19-26.
5. Fulda, S.; Debatin, K.M. Exploiting death receptor signaling pathways for tumor therapy. Biochimica et Biophysica Acta, 2004, 1705, 27-41.
6. Ashkenazi, A.; Dixit, V.M. Death receptors: signaling and modulation. Science, 1998, 281, 1305-1308.
7. Lavrik, I.; Golks, A.; Krammer, P.H. Death receptor signaling. Journal of Cell Science, 2005, 118, 265-267.
8. Peter, M.E.; Krammer, P.H. The CD95(APO-1/Fas) DISC and beyond. Cell Death Diff., 2003, 10, 26-35.
9. Akazawa, Y.; Gores, G.J. Death receptor-mediated liver injury. Semin. Liver Dis., 2007, 27, 327-338.
10. Parkin, D.M.; Bray, F.; Ferlay, J.; Pisani, P. Global cancer statistics, 2002. CA Cancer J. Clin., 2005, 55, 74-108.
11. Parkin, D.M.; Bray, F.; Ferlay, J.; Pisani, P. Estimating the world cancer burden: Globocan 2000. Int. J. Cancer, 2001, 94, 153-156.
12. El-Serag, H.B.; Rudolph, K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology, 2007, 132, 2557-2576.
13. Ogasawara, J.; Watanabe-Fukunaga, R.; Adachi, M.; Matsuzawa, A.; Kasugai, T.; Kitamura, Y.; Itoh, N.; Suda, T.; Nagata, S. Lethal effect of the anti-Fas antibody in mice. Nature, 1993, 364, 806-809.
14. Galle, P.R.; Hofmann, W.J.; Walczak, H.; Schaller, H.; Otto, G.; Stremmel, W.; Krammer, P.H.; Runkel, L. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J. Exp. Med., 1995, 182, 1223-1230.
15. Higaki, K.; Yano, H.; Kojiro, M. Fas antigen expression and its relationship with apoptosis in human hepatocellular carcinoma and noncancerous tissues. Am. J. Path., 1996, 149, 429-437.
16. Ito, Y.; Takeda, T.; Umeshita, K.; Sakon, M.; Wakasa, K.; Matsuura, N.; Monden, M. Fas antigen expression in hepatocellular carcinoma tissues. Oncol. Reports, 1998, 5, 41-44.
17. Fujii, T.; Takayasu, K.; Muramatsu, Y.; Moriyama, N.; Wakao, F.; Kosuge, T.; Takayama, T.; Makuuchi, M.; Yamasaki, S.; Okazaki, N.; et al. Hepatocellular carcinoma with portal tumor thrombus: analysis of factors determining prognosis. Jpn. J. Clin. Oncol., 1993, 23, 105-109.
18. Ikai, I.; Yamaoka, Y.; Yamamoto, Y.; Ozaki, N.; Sakai, Y.; Satoh, S.; Shinkura, N.; Yamamoto, M. Surgical intervention for patients with stage IV-A hepatocellular carcinoma without lymph node metastasis: proposal as a standard therapy. Ann. Surg., 1998, 227, 433-439.
19. Fan, J.; Wu, Z.Q.; Tang, Z.Y.; Zhou, J.; Qiu, S.J.; Ma, Z.C.; Zhou, X.D.; Ye, S.L. Multimodality treatment in hepatocellular carcinoma patients with tumor thrombi in portal vein. World J. Gastroenterol., 2001, 7, 28-32.
20. Llovet, J.M.; Burroughs, A.; Bruix, J. Hepatocellular carcinoma. Lancet, 2003, 362, 1907-1917.
21. Shen, D.W.; Lu, Y.G.; Chin, K.V.; Pastan, I.; Gottesman, M.M. Human hepatocellular carcinoma cell lines exhibit multidrug resistance unrelated to MRD1 gene expression. J. Cell Sci., 1991, 98 (Pt 3), 317-322.
22. Doci, R.; Bignami, P.; Bozzetti, F.; Bonfanti, G.; Audisio, R.; Colombo, M.; Gennari, L. Intrahepatic chemotherapy for unresectable hepatocellular carcinoma. Cancer, 1988, 61, 1983-1987.
23. Befeler, A.S.; Di Bisceglie, A.M. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology, 2002, 122, 1609-1619.
24. Barnett, C.C., Jr.; Curley, S.A. Ablative techniques for hepatocellular carcinoma. Semin. Oncol., 2001, 28, 487-496.
25. Locksley, R.M.; Killeen, N.; Lenardo, M.J. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell, 2001, 104, 487-501.
26. Komori, A.; Yatsunami, J.; Suganuma, M.; Okabe, S.; Abe, S.; Sakai, A.; Sasaki, K.; Fujiki, H. Tumor necrosis factor acts as a tumor promoter in BALB/3T3 cell transformation. Cancer Res., 1993, 53, 1982-1985.
27. Falasca, K.; Ucciferri, C.; Dalessandro, M.; Zingariello, P.; Mancino, P.; Petrarca, C.; Pizzigallo, E.; Conti, P.; Vecchiet, J. Cytokine patterns correlate with liver damage in patients with chronic hepatitis B and C. Ann. Clin. Lab. Sci., 2006, 36, 144-150.
28. Cha, C.; Dematteo, R.P. Molecular mechanisms in hepatocellular carcinoma development. Best Pract. Res. Clin. Gastroenterol., 2005, 19, 25-37.
29. Catalano, M.G.; Fortunati, N.; Arena, K.; Costelli, P.; Aragno, M.; Danni, O.; Boccuzzi, G. Selective up-regulation of tumor necrosis factor receptor I in tumor-bearing rats with cancer-related cachexia. Int. J. Oncol., 2003, 23, 429-436.
30. Jeng, J.E.; Tsai, J.F.; Chuang, L.Y.; Ho, M.S.; Lin, Z.Y.; Hsieh, M.Y.; Chen, S.C.; Chuang, W.L.; Wang, L.Y.; Yu, M.L.; Dai, C.Y.; Chang, J.G. Tumor necrosis factor-alpha 308.2 polymorphism is associated with advanced hepatic fibrosis and higher risk for hepatocellular carcinoma. Neoplasia, 2007, 9, 987-992.
31. Chen, G.; Goeddel, D.V. TNF-R1 signaling: a beautiful pathway. Science, 2002, 296, 1634-1635.
32. Micheau, O.; Tschopp, J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell, 2003, 114, 181-190.
33. Wang, C.Y.; Mayo, M.W.; Korneluk, R.G.; Goeddel, D.V.; Baldwin, A.S., Jr. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science, 1998, 281, 1680-1683.
34. Micheau, O.; Lens, S.; Gaide, O.; Alevizopoulos, K.; Tschopp, J. NF-kappaB signals induce the expression of c-FLIP. Mol. Cell. Biol., 2001, 21, 5299-5305.
35. Mayo, M.W.; Baldwin, A.S. The transcription factor NF-kappaB: control of oncogenesis and cancer therapy resistance. Biochimica et Biophysica Acta, 2000, 1470, M55-62.
36. Dempsey, P.W.; Doyle, S.E.; He, J.Q.; Cheng, G. The signaling adaptors and pathways activated by TNF superfamily. Cytokine Growth Factor Rev., 2003, 14, 193-209.
37. Haybaeck, J.; Zeller, N.; Wolf, M.J.; Weber, A.; Wagner, U.; Kurrer, M.O.; Bremer, J.; Iezzi, G.; Graf, R.; Clavien, P.A.; Thimme, R.; Blum, H.; Nedospasov, S.A.; Zatloukal, K.; Ramzan, M.; Ciesek, S.; Pietschmann, T.; Marche, P.N.; Karin, M.; Kopf, M.; Browning, J.L.; Aguzzi, A.; Heikenwalder, M. A lymphotoxindriven pathway to hepatocellular carcinoma. Cancer Cell, 2009, 16, 295-308.
38. Schattenberg, J.M.; Schuchmann, M.; Galle, P.R. Cell death and hepatocarcinogenesis: Dysregulation of apoptosis signaling pathways. Journal of Gastroenterology and Hepatology, 2011, 26(Suppl 1), 213-219.
39. Sethi, G.; Sung, B.; Kunnumakkara, A.B.; Aggarwal, B.B. Targeting TNF for Treatment of Cancer and Autoimmunity. Adv. Exp. Med. Biol., 2009, 647, 37-51.
40. Russo, M.; Mupo, A.; Spagnuolo, C.; Russo, G.L. Exploring death receptor pathways as selective targets in cancer therapy. Biochem. Pharmacol., 2010, 80, 674-682.
41. Wajant, H.; Gerspach, J.; Pfizenmaier, K. Tumor therapeutics by design: targeting and activation of death receptors. Cytokine Growth Factor Rev., 2005, 16, 55-76.
42. Yan, Y.; Xu, W.; Qian, H.; Zhu, W.; Mao, F.; Zhang, X. Tumstatin45-132-TNFalpha suppresses tumour growth through antiangiogenic effects and cytotoxicity. Biotechnol. App. Biochem., 2010, 56, 119-127.
43. Shibata, H.; Yoshioka, Y.; Ikemizu, S.; Kobayashi, K.; Yamamoto, Y.; Mukai, Y.; Okamoto, T.; Taniai, M.; Kawamura, M.; Abe, Y.; Nakagawa, S.; Hayakawa, T.; Nagata, S.; Yamagata, Y.; Mayumi, T.; Kamada, H.; Tsutsumi, Y. Functionalization of tumor necrosis factor-alpha using phage display technique and PEGylation improves its antitumor therapeutic window. Clin. Cancer Res., 2004, 10, 8293-8300.
44. Gerspach, J.; Pfizenmaier, K.; Wajant, H. Improving TNF as a cancer therapeutic: tailor-made TNF fusion proteins with conserved antitumor activity and reduced systemic side effects. Biofactors, 2009, 35, 364-372.
45. Weichselbaum, R.R.; Kufe, D. Translation of the radio- and chemo-inducible TNFerade vector to the treatment of human cancers. Cancer Gene Ther., 2009, 16, 609-619.
46. Amirkhosravi, A.; Warnes, G.; Biggerstaff, J.; Malik, Z.; May, K.; Francis, J.L. The effect of pentoxifylline on spontaneous and experimental metastasis of the mouse Neuro2a neuroblastoma. Clin. Exp. Metastasis, 1997, 15, 453-461.
47. Hsu, C.; Chen, C.N.; Chen, L.T.; Wu, C.Y.; Yang, P.M.; Lai, M.Y.; Lee, P.H.; Cheng, A.L. Low-dose thalidomide treatment for advanced hepatocellular carcinoma. Oncology, 2003, 65, 242-249.
48. Tracey, D.; Klareskog, L.; Sasso, E.H.; Salfeld, J.G.; Tak, P.P. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol. Ther., 2008, 117, 244-279.
49. Mitoma, H.; Horiuchi, T.; Tsukamoto, H.; Tamimoto, Y.; Kimoto, Y.; Uchino, A.; To, K.; Harashima, S.; Hatta, N.; Harada, M. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arth. Rheum., 2008, 58, 1248-1257.
50. Shen, C.; Van Assche, G.; Rutgeerts, P.; Ceuppens, J.L. Caspase activation and apoptosis induction by adalimumab: demonstration in vitro and in vivo in a chimeric mouse model. Inflamm. Bowel Dis., 2006, 12, 22-28.
51. Seitz, S.J.; Schleithoff, E.S.; Koch, A.; Schuster, A.; Teufel, A.; Staib, F.; Stremmel, W.; Melino, G.; Krammer, P.H.; Schilling, T.; Muller, M. Chemotherapy-induced apoptosis in hepatocellular carcinoma involves the p53 family and is mediated via the extrinsic and the intrinsic pathway. Inter. J. Cancer, 2010, 126, 2049-2066.
52. Gressner, O.; Schilling, T.; Lorenz, K.; Schulze Schleithoff, E.; Koch, A.; Schulze-Bergkamen, H.; Lena, A.M.; Candi, E.; Terrinoni, A.; Catani, M.V.; Oren, M.; Melino, G.; Krammer, P.H.; Stremmel, W.; Muller, M. TAp63alpha induces apoptosis by activating signaling via death receptors and mitochondria. EMBO J., 2005, 24, 2458-2471.
53. Muller, M.; Schilling, T.; Sayan, A.E.; Kairat, A.; Lorenz, K.; Schulze-Bergkamen, H.; Oren, M.; Koch, A.; Tannapfel, A.; Stremmel, W.; Melino, G.; Krammer, P.H. TAp73/Delta Np73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma. Cell Death Diff., 2005, 12, 1564-1577.
54. Orlowski, R.Z.; Baldwin, A.S., Jr. NF-kappaB as a therapeutic target in cancer. Trends Mol. Med., 2002, 8, 385-389.
55. Wang, C.Y.; Cusack, J.C., Jr.; Liu, R.; Baldwin, A.S., Jr. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat. Med., 1999, 5, 412-417.
56. Lee, K.Y.; Chang, W.; Qiu, D.; Kao, P.N.; Rosen, G.D. PG490 (triptolide) cooperates with tumor necrosis factor-alpha to induce apoptosis in tumor cells. J. Biol. Chem., 1999, 274, 13451-13455.
57. Hideshima, T.; Mitsiades, C.; Akiyama, M.; Hayashi, T.; Chauhan, D.; Richardson, P.; Schlossman, R.; Podar, K.; Munshi, N.C.; Mitsiades, N.; Anderson, K.C. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood, 2003, 101, 1530-1534.
58. Shin, D.H.; Chun, Y.S.; Lee, D.S.; Huang, L.E.; Park, J.W. Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIHmediated repression of hypoxia-inducible factor-1. Blood, 2008, 111, 3131-3136.
59. Garcia-Roman, R.; Salazar-Gonzalez, D.; Rosas, S.; Arellanes-Robledo, J.; Beltran-Ramirez, O.; Fattel-Fazenda, S.; Villa-Trevino, S. The differential NF-kB modulation by S-adenosyl-Lmethionine, N-acetylcysteine and quercetin on the promotion stage of chemical hepatocarcinogenesis. Free Rad. Res., 2008, 42, 331-343.
60. Sprick, M.R.; Rieser, E.; Stahl, H.; Grosse-Wilde, A.; Weigand, M.A.; Walczak, H. Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8. EMBO J., 2002, 21, 4520-4530.
61. Golks, A.; Brenner, D.; Fritsch, C.; Krammer, P.H.; Lavrik, I.N. c- FLIPR, a new regulator of death receptor-induced apoptosis. J. Biol.Chem., 2005, 280, 14507-14513.
62. Lavrik, I.; Krueger, A.; Schmitz, I.; Baumann, S.; Weyd, H.; Krammer, P.H.; Kirchhoff, S. The active caspase-8 heterotetramer is formed at the CD95 DISC. Cell Death Diff., 2003, 10, 144-145.
63. Irmler, M.; Thome, M.; Hahne, M.; Schneider, P.; Hofmann, K.; Steiner, V.; Bodmer, J.L.; Schroter, M.; Burns, K.; Mattmann, C.; Rimoldi, D.; French, L.E.; Tschopp, J. Inhibition of death receptor signals by cellular FLIP. Nature, 1997, 388, 190-195.
64. Kreuz, S.; Siegmund, D.; Rumpf, J.J.; Samel, D.; Leverkus, M.; Janssen, O.; Hacker, G.; Dittrich-Breiholz, O.; Kracht, M.; Scheurich, P.; Wajant, H. NFkappaB activation by Fas is mediated through FADD, caspase-8, and RIP and is inhibited by FLIP. J. Cell Biol., 2004, 166, 369-380.
65. Okamoto, K.; Fujisawa, J.; Reth, M.; Yonehara, S. Human T-cell leukemia virus type-I oncoprotein Tax inhibits Fas-mediated apoptosis by inducing cellular FLIP through activation of NFkappaB. Genes Cells, 2006, 11, 177-191.
66. Muller, M.; Strand, S.; Hug, H.; Heinemann, E.M.; Walczak, H.; Hofmann, W.J.; Stremmel, W.; Krammer, P.H.; Galle, P.R. Druginduced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J. Clin.Invest., 1997, 99, 403-413.
67. Ito, Y.; Monden, M.; Takeda, T.; Eguchi, H.; Umeshita, K.; Nagano, H.; Nakamori, S.; Dono, K.; Sakon, M.; Nakamura, M.; Tsujimoto, M.; Nakahara, M.; Nakao, K.; Yokosaki, Y.; Matsuura, N. The status of Fas and Fas ligand expression can predict recurrence of hepatocellular carcinoma. Br. J. Cancer, 2000, 82, 1211-1217.
68. Volkmann, M.; Schiff, J.H.; Hajjar, Y.; Otto, G.; Stilgenbauer, F.; Fiehn, W.; Galle, P.R.; Hofmann, W.J. Loss of CD95 expression is linked to most but not all p53 mutants in European hepatocellular carcinoma. J. Mol. Med., 2001, 79, 594-600.
69. Lee, S.H.; Shin, M.S.; Lee, H.S.; Bae, J.H.; Lee, H.K.; Kim, H.S.; Kim, S.Y.; Jang, J.J.; Joo, M.; Kang, Y.K.; Park, W.S.; Park, J.Y.; Oh, R.R.; Han, S.Y.; Lee, J.H.; Kim, S.H.; Lee, J.Y.; Yoo, N.J. Expression of Fas and Fas-related molecules in human hepatocellular carcinoma. Hum. Pathol., 2001, 32, 250-256.
70. Nishimura, Y.; Hirabayashi, Y.; Matsuzaki, Y.; Musette, P.; Ishii, A.; Nakauchi, H.; Inoue, T.; Yonehara, S. In vivo analysis of Fas antigen-mediated apoptosis: effects of agonistic anti-mouse Fas mAb on thymus, spleen and liver. Inter. Immunol., 1997, 9, 307-316.
71. Ichikawa, K.; Yoshida-Kato, H.; Ohtsuki, M.; Ohsumi, J.; Yamaguchi, J.; Takahashi, S.; Tani, Y.; Watanabe, M.; Shiraishi, A.; Nishioka, K.; Yonehara, S.; Serizawa, N. A novel murine antihuman Fas mAb which mitigates lymphadenopathy without hepatotoxicity. Inter. Immunol., 2000, 12, 555-562.
72. Nakayama, J.; Ogawa, Y.; Yoshigae, Y.; Onozawa, Y.; Yonemura, A.; Saito, M.; Ichikawa, K.; Yamoto, T.; Komai, T.; Tatsuta, T.; Ohtsuki, M. A humanized anti-human Fas antibody, R-125224, induces apoptosis in type I activated lymphocytes but not in type II cells. Inter. Immunol., 2006, 18, 113-124.
73. Rensing-Ehl, A.; Frei, K.; Flury, R.; Matiba, B.; Mariani, S.M.; Weller, M.; Aebischer, P.; Krammer, P.H.; Fontana, A. Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo. Eur J. Immunol., 1995, 25, 2253-2258.
74. Suda, T.; Hashimoto, H.; Tanaka, M.; Ochi, T.; Nagata, S. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J. Exp. Med., 1997, 186, 2045-2050.
75. Schneider, P.; Holler, N.; Bodmer, J.L.; Hahne, M.; Frei, K.; Fontana, A.; Tschopp, J. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J. Exp. Med., 1998, 187, 1205-1213.
76. Aoki, K.; Kurooka, M.; Chen, J.J.; Petryniak, J.; Nabel, E.G.; Nabel, G.J. Extracellular matrix interacts with soluble CD95L: retention and enhancement of cytotoxicity. Nat. Immunol., 2001, 2, 333-337.
77. Bremer, E.; de Bruyn, M.; Wajant, H.; Helfrich, W. Targeted cancer immunotherapy using ligands of the tumor necrosis factor super- family. Curr. Drug Tar., 2009, 10, 94-103.
78. Rubinchik, S.; Wang, D.; Yu, H.; Fan, F.; Luo, M.; Norris, J.S.; Dong, J.Y. A complex adenovirus vector that delivers FASL-GFP with combined prostate-specific and tetracycline-regulated expression. Mol. Ther., 2001, 4, 416-426.
79. Thompson, C.B. Apoptosis in the pathogenesis and treatment of disease. Science, 1995, 267, 1456-1462.
80. Liu, Z.; Liu, R.; Qiu, J.; Yin, P.; Luo, F.; Su, J.; Li, W.; Chen, C.; Fan, X.; Zhang, J.; Zhuang, G. Combination of human Fas (CD95/ Apo-1) ligand with adriamycin significantly enhances the efficacy of antitumor response. Cell Mol. Immunol., 2009, 6, 167-174.
81. Verbrugge, I.; Wissink, E.H.; Rooswinkel, R.W.; Jongsma, J.; Beltraminelli, N.; Dupuis, M.; Borst, J.; Verheij, M. Combining radiotherapy with APO010 in cancer treatment. Clin. Cancer Res., 2009, 15, 2031-2038.
82. Muller, M.; Wilder, S.; Bannasch, D.; Israeli, D.; Lehlbach, K.; Li-Weber, M.; Friedman, S.L.; Galle, P.R.; Stremmel, W.; Oren, M.; Krammer, P.H. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J. Exp. Med., 1998, 188, 2033-2045.
83. Kavurma, M.M.; Khachigian, L.M. Signaling and transcriptional control of Fas ligand gene expression. Cell Death Diff., 2003, 10, 36-44.
84. Fukazawa, T.; Fujiwara, T.; Morimoto, Y.; Shao, J.; Nishizaki, M.; Kadowaki, Y.; Hizuta, A.; Owen-Schaub, L.B.; Roth, J.A.; Tanaka, N. Differential involvement of the CD95 (Fas/APO-1) receptor/ ligand system on apoptosis induced by the wild-type p53 gene transfer in human cancer cells. Oncogene, 1999, 18, 2189-2199.
85. Gajate, C.; Mollinedo, F. The antitumor ether lipid ET-18-OCH(3) induces apoptosis through translocation and capping of Fas/CD95 into membrane rafts in human leukemic cells. Blood, 2001, 98, 3860-3863.
86. Jimenez-Lopez, J.M.; Rios-Marco, P.; Marco, C.; Segovia, J.L.; Carrasco, M.P. Alterations in the homeostasis of phospholipids and cholesterol by antitumor alkylphospholipids. Lipids Health Dis., 2010, 9, 33.
87. Medema, J.P.; de Jong, J.; van Hall, T.; Melief, C.J.; Offringa, R. Immune escape of tumors in vivo by expression of cellular FLICEinhibitory protein. J. Exp. Med., 1999, 190,1033-1038.
88. Nakamura, M.; Nagano, H.; Sakon, M.; Yamamoto, T.; Ota, H.; Wada, H.; Damdinsuren, B.; Noda, T.; Marubashi, S.; Miyamoto, A.; Takeda, Y.; Umeshita, K.; Nakamori, S.; Dono, K.; Monden, M. Role of the Fas/FasL pathway in combination therapy with interferon- alpha and fluorouracil against hepatocellular carcinoma in vitro. J. Hepatol., 2007, 46, 77-88.
89. Minucci, S.; Pelicci, P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer, 2006, 6, 38-51.
90. Weiller, M.; Weiland, T.; Dunstl, G.; Sack, U.; Kunstle, G.; Wendel, A. Differential immunotoxicity of histone deacetylase inhibitors on malignant and naive hepatocytes. Exp. Toxicol. Pathol., 2010. PMID: 20537879.
91. Schuchmann, M.; Schulze-Bergkamen, H.; Fleischer, B.; Schattenberg, J.M.; Siebler, J.; Weinmann, A.; Teufel, A.; Worns, M.; Fischer, T.; Strand, S.; Lohse, A.W.; Galle, P.R. Histone deacetylase inhibition by valproic acid down-regulates c-FLIP/CASH and sensitizes hepatoma cells towards CD95- and TRAIL receptormediated apoptosis and chemotherapy. Oncol. Reports, 2006, 15, 227-230.
92. Higuchi, H.; Yoon, J.H.; Grambihler, A.; Werneburg, N.; Bronk, S.F.; Gores, G.J. Bile acids stimulate cFLIP phosphorylation enhancing TRAIL-mediated apoptosis. J. Biol. Chem., 2003, 278, 454-461.
93. Wiley, S.R.; Schooley, K.; Smolak, P.J.; Din, W.S.; Huang, C.P.; Nicholl, J.K.; Sutherland, G.R.; Smith, T.D.; Rauch, C.; Smith, C.A.; et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity, 1995, 3, 673-682.
94. Daniels, R.A.; Turley, H.; Kimberley, F.C.; Liu, X.S.; Mongkolsapaya, J.; Ch'En, P.; Xu, X.N.; Jin, B.Q.; Pezzella, F.; Screaton, G.R. Expression of TRAIL and TRAIL receptors in normal and malignant tissues. Cell Res, 2005, 15, 430-438.
95. Jo, M.; Kim, T.H.; Seol, D.W.; Esplen, J.E.; Dorko, K.; Billiar, T.R.; Strom, S.C. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat. Med., 2000, 6, 564-567.
96. Lawrence, D.; Shahrokh, Z.; Marsters, S.; Achilles, K.; Shih, D.; Mounho, B.; Hillan, K.; Totpal, K.; DeForge, L.; Schow, P.; Hooley, J.; Sherwood, S.; Pai, R.; Leung, S.; Khan, L.; Gliniak, B.; Bussiere, J.; Smith, C.A.; Strom, S.S.; Kelley, S.; Fox, J.A.; Thomas, D.; Ashkenazi, A. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat. Med., 2001, 7, 383-385.
97. Spierings, D.C.; de Vries, E.G.; Vellenga, E.; van den Heuvel, F.A.; Koornstra, J.J.; Wesseling, J.; Hollema, H.; de Jong, S. Tissue distribution of the death ligand TRAIL and its receptors. J. Histochem. Cytochem., 2004, 52, 821-831.
98. Koehler, B.C.; Urbanik, T.; Vick, B.; Boger, R.J.; Heeger, S.; Galle, P.R.; Schuchmann, M.; Schulze-Bergkamen, H. TRAILinduced apoptosis of hepatocellular carcinoma cells is augmented by targeted therapies. World J. Gastroenterol., 2009, 15, 5924-5935.
99. Eichhorst, S.T. Modulation of apoptosis as a target for liver disease. Exp. Opin. Therapeut. Targets, 2005, 9, 83-99.
100. Kriegl, L.; Jung, A.; Engel, J.; Jackstadt, R.; Gerbes, A.L.; Gallmeier, E.; Reiche, J.A.; Hermeking, H.; Rizzani, A.; Bruns, C.J.; Kolligs, F.T.; Kirchner, T.; Goke, B.; De Toni, E.N. Expression, cellular distribution, and prognostic relevance of TRAIL receptors in hepatocellular carcinoma. Clin. Cancer Res., 2010, 16, 5529-5538.
101. Cretney, E.; Takeda, K.; Yagita, H.; Glaccum, M.; Peschon, J.J.; Smyth, M.J. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J. Immunol., 2002, 168, 1356-1361.
102. Kischkel, F.C.; Lawrence, D.A.; Chuntharapai, A.; Schow, P.; Kim, K.J.; Ashkenazi, A. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity, 2000, 12, 611-620.
103. Sprick, M.R.; Weigand, M.A.; Rieser, E.; Rauch, C.T.; Juo, P.; Blenis, J.; Krammer, P.H.; Walczak, H. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity, 2000, 12, 599-609.
104. Kavurma, M.M.; Schoppet, M.; Bobryshev, Y.V.; Khachigian, L.M.; Bennett, M.R. TRAIL stimulates proliferation of vascular smooth muscle cells via activation of NF-kappaB and induction of insulin-like growth factor-1 receptor. J. Biol. Chem., 2008, 283, 7754-7762.
105. Song, J.H.; Tse, M.C.; Bellail, A.; Phuphanich, S.; Khuri, F.; Kneteman, N.M.; Hao, C. Lipid rafts and nonrafts mediate tumor necrosis factor related apoptosis-inducing ligand induced apoptotic and nonapoptotic signals in non small cell lung carcinoma cells. Cancer Res., 2007, 67, 6946-6955.
106. Johnstone, R.W.; Frew, A.J.; Smyth, M.J. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat. Rev. Cancer, 2008, 8, 782-798.
107. Ashkenazi, A.; Pai, R.C.; Fong, S.; Leung, S.; Lawrence, D.A.; Marsters, S.A.; Blackie, C.; Chang, L.; McMurtrey, A.E.; Hebert, A.; DeForge, L.; Koumenis, I.L.; Lewis, D.; Harris, L.; Bussiere, J.; Koeppen, H.; Shahrokh, Z.; Schwall, R.H. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest., 1999, 104, 155-162.
108. Kelley, S.K.; Harris, L.A.; Xie, D.; Deforge, L.; Totpal, K.; Bussiere, J.; Fox, J.A. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J. Pharmacol. Exp. Ther., 2001, 299, 31-38.
109. Holoch, P.A.; Griffith, T.S. TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies. Eur. J. Pharmacol., 2009, 625, 63-72.
110. Griffith, T.S.; Anderson, R.D.; Davidson, B.L.; Williams, R.D.; Ratliff, T.L. Adenoviral-mediated transfer of the TNF-related apoptosis- inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis. J Immunol, 2000, 165, 2886-2894.
111. Ma, H.; Liu, Y.; Liu, S.; Kung, H.F.; Sun, X.; Zheng, D.; Xu, R. Recombinant adeno-associated virus-mediated TRAIL gene therapy suppresses liver metastatic tumors. Int. J. Cancer, 2005, 116, 314-321.
112. Liu, X.; Yue, P.; Khuri, F.R.; Sun, S.Y. p53 upregulates death receptor 4 expression through an intronic p53 binding site. Cancer Res., 2004, 64, 5078-5083.
113. Roue, G.; Perez-Galan, P.; Lopez-Guerra, M.; Villamor, N.; Campo, E.; Colomer, D. Selective inhibition of IkappaB kinase sensitizes mantle cell lymphoma B cells to TRAIL by decreasing cellular FLIP level. J. Immunol., 2007, 178, 1923-1930.
114. Voortman, J.; Resende, T.P.; Abou El Hassan, M.A.; Giaccone, G.; Kruyt, F.A. TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib. Mol. Cancer Ther., 2007, 6, 2103-2112.
115. Zhao, X.; Qiu, W.; Kung, J.; Peng, X.; Yegappan, M.; Yen-Lieberman, B.; Hsi, E.D. Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: a gene expression profiling study with implications for potential combination therapies. Leukemia Res., 2008, 32, 275-285.
116. Ganten, T.M.; Koschny, R.; Haas, T.L.; Sykora, J.; Li-Weber, M.; Herzer, K.; Walczak, H. Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL. Hepatology, 2005, 42, 588-597.
117. Koschny, R.; Ganten, T.M.; Sykora, J.; Haas, T.L.; Sprick, M.R.; Kolb, A.; Stremmel, W.; Walczak, H. TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window. Hepatology, 2007, 45, 649-658.
118. Luster, T.A.; Carrell, J.A.; McCormick, K.; Sun, D.; Humphreys, R. Mapatumumab and lexatumumab induce apoptosis in TRAILR1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib. Mol. Cancer Ther., 2009, 8, 292-302.
119. Brooks, A.D.; Ramirez, T.; Toh, U.; Onksen, J.; Elliott, P.J.; Murphy, W.J.; Sayers, T.J. The proteasome inhibitor bortezomib (Velcade) sensitizes some human tumor cells to Apo2L/TRAIL mediated apoptosis. Ann. NY Acad. Sci., 2005, 1059, 160-167.
120. Rosato, R.R.; Almenara, J.A.; Coe, S.; Grant, S. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. Cancer Res., 2007, 67, 9490-9500.
121. Fulda, S.; Debatin, K.M. HDAC inhibitors: double edge sword for TRAIL cancer therapy?, Cancer Biol. Ther., 2005, 4, 1113-1115.
122. Pathil, A.; Armeanu, S.; Venturelli, S.; Mascagni, P.; Weiss, T.S.; Gregor, M.; Lauer, U.M.; Bitzer, M. HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL. Hepatology, 2006, 43, 425-434.
123. Carlisi, D.; Lauricella, M.; D'Anneo, A.; Emanuele, S.; Angileri, L.; Di Fazio, P.; Santulli, A.; Vento, R.; Tesoriere, G. The histone deacetylase inhibitor suberoylanilide hydroxamic acid sensitises human hepatocellular carcinoma cells to TRAIL-induced apoptosis by TRAIL-DISC activation. Eur. J. Cancer, 2009, 45, 2425-2438.
124. Schmidt, C.M.; McKillop, I.H.; Cahill, P.A.; Sitzmann, J.V. Increased MAPK expression and activity in primary human hepatocellular carcinoma. Biochem. Biophys. Res. Commun., 1997, 236, 54-58.
125. Sakurai, T.; Maeda, S.; Chang, L.; Karin, M. Loss of hepatic NFkappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. Proc. Natl. Acad. Sci. USA, 2006, 103, 10544-10551.
126. Eferl, R.; Ricci, R.; Kenner, L.; Zenz, R.; David, J.P.; Rath, M.; Wagner, E.F. Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53. Cell, 2003, 112, 181-192.
127. Mucha, S.R.; Rizzani, A.; Gerbes, A.L.; Camaj, P.; Thasler, W.E.; Bruns, C.J.; Eichhorst, S.T.; Gallmeier, E.; Kolligs, F.T.; Goke, B.; De Toni, E.N. JNK inhibition sensitises hepatocellular carcinoma cells but not normal hepatocytes to the TNF-related apoptosisinducing ligand. Gut, 2009, 58, 688-698.
128. Ray, S.; Bucur, O.; Almasan, A. Sensitization of prostate carcinoma cells to Apo2L/TRAIL by a Bcl-2 family protein inhibitor. Apoptosis, 2005, 10, 1411-1418.
129. Herbst, R.S.; Eckhardt, S.G.; Kurzrock, R.; Ebbinghaus, S.; O'Dwyer, P.J.; Gordon, M.S.; Novotny, W.; Goldwasser, M.A.; Tohnya, T.M.; Lum, B.L.; Ashkenazi, A.; Jubb, A.M.; Mendelson, D.S. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J. Clin. Oncol., 2010, 28, 2839-2846.
130. Tolcher, A.W.; Mita, M.; Meropol, N.J.; von Mehren, M.; Patnaik, A.; Padavic, K.; Hill, M.; Mays, T.; McCoy, T.; Fox, N.L.; Halpern, W.; Corey, A.; Cohen, R.B. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factorrelated apoptosis-inducing ligand receptor-1. J. Clin. Oncol., 2007, 25, 1390-1395.
131. Leong, S.; Cohen, R.B.; Gustafson, D.L.; Langer, C.J.; Camidge, D.R.; Padavic, K.; Gore, L.; Smith, M.; Chow, L.Q.; von Mehren, M.; O'Bryant, C.; Hariharan, S.; Diab, S.; Fox, N.L.; Miceli, R.; Eckhardt, S.G. Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study. J. Clin. Oncol., 2009, 27, 4413-4421.
132. Greco, F.A.; Bonomi, P.; Crawford, J.; Kelly, K.; Oh, Y.; Halpern, W.; Lo, L.; Gallant, G.; Klein, J. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced nonsmall cell lung cancer. Lung Cancer, 2008, 61, 82-90.
133. Wakelee, H.A.; Patnaik, A.; Sikic, B.I.; Mita, M.; Fox, N.L.; Miceli, R.; Ullrich, S.J.; Fisher, G.A.; Tolcher, A.W. Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors. Ann. Oncol., 2010, 21, 376-381.
134. Camidge, D.R. Apomab: an agonist monoclonal antibody directed against Death Receptor 5/TRAIL-Receptor 2 for use in the treatment of solid tumors. Exp. Opin. Biol. Ther., 2008, 8, 1167-1176.
135. Llovet, J.M.; Ricci, S.; Mazzaferro, V.; Hilgard, P.; Gane, E.; Blanc, J.F.; de Oliveira, A.C.; Santoro, A.; Raoul, J.L.; Forner, A.; Schwartz, M.; Porta, C.; Zeuzem, S.; Bolondi, L.; Greten, T.F.; Galle, P.R.; Seitz, J.F.; Borbath, I.; Haussinger, D.; Giannaris, T.; Shan, M.; Moscovici, M.; Voliotis, D.; Bruix, J. Sorafenib in advanced hepatocellular carcinoma. New England J. Med., 2008, 359, 378-390.